Biotech
Freenome
Freenome raises $254M Series D at $1.2B valuation
South San Francisco, CAFebruary 15, 20241 min read
Latest funding
$254M
Valuation
$1.2B
Latest Round
Series D
Employees
300+
Freenome: Series D Funding Round
Freenome has successfully raised $254M in Series D funding, reaching a valuation of $1.2B.
Company Overview
Multi-cancer early detection blood test developer using AI
Funding Details
The Series D round was led by Roche, with participation from a16z Life Sciences, ARK Investments.
Company Information
- Headquarters: South San Francisco, CA
- Founded: 2014
- Employees: 300+
- Category: Biotech
Investment
Freenome plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Roche: Verified investor in Series D
- a16z Life Sciences: Verified investor in Series D
- ARK Investments: Verified investor in Series D
Company Info
Headquarters
South San Francisco, CA
Founded
2014
Team Size
300+
Last Round
$254M(Feb 2024)
Investors (3)
R
RocheLeadLead Investor
Verified investor in Series D
a
a16z Life SciencesInvestor
Verified investor in Series D
A
ARK InvestmentsInvestor
Verified investor in Series D
Share
Related Reports
Biotech
AusperBio
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
David Chen
Dec 30, 2025
0 min read•$73M Series B
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started